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Introduction
Colorectal cancer is a common cancer, with 412 900 new 
cases and 207 400 deaths in Europe in 2006.1 7–29% of 
patients with colorectal cancer present with a bowel 
obstruction.2,3 Conventionally, these patients receive 
emergency surgery to restore luminal patency. Emergency 
operations are associated with mortality in 15–34% of 
patients and morbidity in 32–64%, despite advances in 
perioperative care.3–7 Several surgical techniques can be 
used to treat this disorder. Usually, an ostomy is created 
with the intention of secondary closure, but in many 
patients, these ostomies will not be closed.2,5 Patients 
with a permanent stoma frequently report complications 
and poorer health-related quality of life than do patients 
without colostomy.8–11
In the early 1990s, colonic stenting was introduced to 
restore luminal patency in patients with malignant 
obstruction of the left side of the colon. Stent placement 
before elective surgery, also known as a bridge to surgery, 
improved the clinical condition of the patient and seemed 
to decrease mortality, morbidity, and number of 
colostomies in uncontrolled studies.5,6,12,13 Additionally, 
this temporary procedure enables accurate tumour 
staging and prevents the need for surgery in patients 
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Summary
Background Colonic stenting as a bridge to elective surgery is an alternative for emergency surgery in patients with 
acute malignant colonic obstruction, but its benefi ts are uncertain. We aimed to establish whether colonic stenting 
has better health outcomes than does emergency surgery.
Methods Patients with acute obstructive left-sided colorectal cancer were enrolled from 25 hospitals in the Netherlands 
and randomly assigned (1:1 ratio) to receive colonic stenting as a bridge to elective surgery or emergency surgery. The 
randomisation sequence was computer generated with permuted blocks and was stratifi ed by centre; treatment 
allocation was concealed by use of a web-based application. Investigators and patients were unmasked to treatment 
assignment. The primary outcome was mean global health status during a 6-month follow-up, which was assessed 
with the QL2 subscale of the European Organisation for Research and Treatment of Cancer quality-of-life questionnaire 
(EORTC QLQ-C30). Analysis was by intention to treat. This study is registered, number ISRCTN46462267.
Findings Between March 9, 2007, and Aug 27, 2009, 98 patients were assigned to receive colonic stenting (n=47 patients) 
or emergency surgery (n=51). Two successive interim analyses showed increased 30-day morbidity in the colonic 
stenting group, with an absolute risk increase of 0·19 (95% CI –0·06 to 0·41) in analysis of the fi rst 60 patients (14 of 
28 patients receiving colonic stenting vs 10 of 32 receiving emergency surgery), and an absolute risk increase of 0·19 
(–0·01 to 0·37) in analysis of the fi rst 90 patients (23 of 47 patients vs 13 of 43). In accordance with the advice of the data 
safety monitoring committee, the study was suspended on Sept 18, 2009, and ended on March 12, 2010. At the fi nal 
analysis of 98 patients, mean global health status during follow-up was 63·0 (SD 23·8) in the colonic stenting group 
and 61·4 (SD 21·9) in the emergency surgery group; after adjustment for baseline values, mean global health status did 
not diff er between treatment groups (–4·7, 95% CI –14·8 to 5·5, p=0·36). No diff erence was recorded between treatment 
groups in 30-day mortality (absolute risk diff erence –0·01, 95% CI –0·14 to 0·12, p=0·89), overall mortality (–0·02, 
–0·17 to 0·14, p=0·84), morbidity (–0·08, –0·27 to 0·11, p=0·43), and stoma rates at latest follow-up (0·09, –0·10 to 0·27, 
p=0·35). However, the emergency surgery group had an increased stoma rate directly after initial intervention (0·23, 
0·04 to 0·40, p=0·016) and a reduced frequency of stoma-related problems (between-group diff erence –12·0, 
–23·7 to –0·2, p=0·046). The most common serious adverse events were abscess (three in the colonic stenting group vs 
four in the emergency surgery group), perforations (six vs none), and anastomotic leakage (fi ve vs one), and the most 
common adverse events were pneumonia (three vs one) and wound infection (one vs three).
Interpretation Colonic stenting has no decisive clinical advantages to emergency surgery. It could be used as an 
alternative treatment in as yet undefi ned subsets of patients, although with caution because of concerns about tumour 
spread caused by perforations.
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with disseminated disease or unacceptable surgical risk. 
In these patients, the colonic stent can serve as permanent 
palliation. In a systematic review of 54 uncontrolled trials 
and case reports, self-expandable metal stents were 
technically successful in 91·9% of patients and clinically 
successful in 71·7% of patients when used as a bridge to 
surgery.14 Major stent-procedure and stent-related 
complications were perforation (3·8%), stent migration 
(11·8%) and reobstruction (7·3%). The stent-procedure 
related mortality was less than 1%.14 Perforation is a 
particular threat because it can lead to subsequent 
peritoneal tumour spill, changing a potentially curable 
disease into an incurable one.
Until now, colonic stenting has mainly been undertaken 
by experts in tertiary centres and published results are 
often retrospective or uncontrolled. Stent insertion needs 
to be properly assessed in randomised controlled trials.15 
We did a randomised assessment of colonic stenting 
versus emergency surgery, with respect to global health 
status, mortality, morbidity, other quality-of-life 
dimensions, and stoma rates.
Methods
Patients
Patients presenting with an acute left-sided colorectal 
obstruction presumed to be caused by a colonic 
malignancy were enrolled consecutively from 
25 participating Dutch hospitals (four university and 
21 non-university teaching hospitals). Eligible patients 
were aged 18 years or older, had clinical signs of severe 
colonic obstruction that had existed for less than 1 week, 
and had dilation of the colon on either plain abdominal 
radiograph, with typical abnormalities on a gastrografi n 
enema study, or contrast-enhanced CT scan. The 
imaging modalities had to be compatible with a total or 
subtotal malignant colonic obstruction, and obstruction 
had to be located in the left side of the colon (descending 
colon, sigmoid, or rectum). Patients were excluded for 
the following reasons: signs of peritonitis, perforation, 
fever, sepsis, or other serious complications demanding 
urgent surgery; physical status of class 4 or 5 according 
to the American Society of Anesthesiologists; 
obstruction caused by a non-colonic malignancy or a 
benign disease; distal tumour margin of less than 10 cm 
from the anal verge; or inability to complete self-report 
quality-of-life questionnaires.
Recruitment started after the local medical ethical 
committees of the participating centres approved the 
trial. All patients provided written informed consent.
Randomisation and masking
Patients were randomly assigned (1:1 ratio) to receive 
colonic stenting as a bridge to surgery or emergency 
surgery. Computer-generated lists with random permuted 
blocks of size four or six per stratum were programmed by 
the independent Department of Clinical Epidemiology and 
Biostatistics of the Academic Medical Centre (University of 
Amsterdam, Amsterdam, Netherlands), stored centrally 
on a server at the Academic Medical Centre, and accessible 
to the local investigator through a web-based application. 
Stratifi cation was by participating centre. At the moment 
an eligible patient gave informed consent, the local 
investigator called the principal investigator. The 
investigator logged in on the web-based application and 
entered the patient’s details and a specifi c centre code. 
After completion of these data the randomisation result 
immediately appeared on the computer screen and was 
reported back to the local investigator.
Because of the obvious strategies under assessment, 
neither patients nor physicians delivering therapy and 
completing case record forms were masked to treatment 
assignment. All complications were masked for group 
assignment by the principal investigator and presented 
to PF and WAB for interpretation. The data safety 
monitoring committee (DSMC) assessed the interim 
analysis, and the fi nal analysis was done by the study 
statistician and the principal investigator.
Procedures
Interventions were started within 24 h of randomisation. 
Colonic stenting was done by experienced endoscopists 
(who had placed ≥20 enteral stents including at least ten 
colonic stents), supported by a radiology assistant for 
fl uoroscopy. Before colonic stenting was attempted, the 
distal colon was prepared with a 133 mL sodium 
phosphate enema. If a standard colonoscope or 
sigmoidoscope could traverse the lesion or the lesion 
seemed to be benign, stent placement was not done. 
Dilation of the obstructive lesion before stent placement 
was forbidden. Stents were placed according to the 
standards of the collaborative Dutch Stent-In study 
group.16 If stent placement failed or symptoms of colonic 
obstruction did not resolve within 3 days, patients were 
treated surgically. Candidates for elective surgery were 
preferably operated on 5–14 days after inclusion, and no 
later than 4 weeks after inclusion. In the absence of data 
from published reports, the collaborative Dutch Stent-In 
study group decided on this timeframe on the basis that 
decompression should actually start directly after stent 
placement, but the colonic wall might take some time to 
recover, and time might be needed for the clinical 
condition of the patient to improve and adequate staging 
to be done. Conversely, elective surgery should not be 
postponed too long because of the increasing risk of stent 
perforation. Type and extent of surgery were selected by 
the treating surgeon.
In the emergency surgery group, patients were operated 
on according to conventional standards. In case of a 
primary colostomy, restoration of bowel continuity was 
attempted within 3–6 months.
After the initial intervention, further diagnostic work-
up was done. In both treatment groups, the primary 
intervention was defi nitive if the patient refused operation 
(or reoperation) or had incurable metastatic disease, or 
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operation (or reoperation) was judged to carry an 
unacceptable risk (American Society of Anesthesiologists 
class 4 or 5). For further specifi cations of the interventions, 
see the published protocol.17 In accordance with the 
intention-to-treat principle, patients not treated according 
to their random assignment, irrespective of the reason, 
were neither crossed over nor excluded.
The primary outcome was mean global health status as 
assessed with the QL2 subscale of the European 
Organisation for Research and Treatment of Cancer 
(EORTC) quality-of-life questionnaire (EORTC QLQ-C30) 
during a 6-month follow-up.18 This measure was chosen 
because the outcome of the treatments, such as need for a 
stoma, incisional hernia, lengthy intensive care, and 
hospital stay, might aff ect patients’ quality of life.
Secondary outcomes were mortality, morbidity, other 
quality-of-life dimensions, and stoma rate. Mortality was 
assessed as procedure-related mortality within 30 days 
after intervention and as overall mortality during follow-
up. Morbidity was defi ned as any event leading to hospital 
admission or extending hospital stay, and was assessed 
throughout follow-up. This description was based on the 
defi nition of a serious adverse event according to the 
good clinical practice guideline from the European 
Medicines Agency. Any untoward medical occurrences 
in patients other than serious adverse events were 
classifi ed as other adverse events. Morbidity and other 
adverse events are reported together as complications.
Cancer-specifi c and tumour-specifi c quality-of-life 
assessments were done with EORTC QLQ-C30 and 
EORTC QLQ-CR38, respectively.19 The EQ-5D 
questionnaire20 was used to calculate quality-adjusted life-
years in a planned cost-eff ectiveness analysis. After 
protocol publication,17 but before start of the study, we 
realised that the stoma rate should have been included as 
an outcome because a stoma might aff ect quality of life 
and costs. Therefore, the stoma rate was added to the 
secondary outcomes, and was recorded at completion of 
the initial intervention (emergency surgery or colonic stent 
placement followed by surgery) and at latest follow-up.
After intervention, quality of life, mortality, morbidity, 
and stoma rate were assessed until death, withdrawal of 
informed consent, or 6-month follow-up, whichever came 
fi rst. Quality-of-life questionnaires were fi lled out at 
baseline and at 4, 12, and 24 weeks after inclusion. 
Questionnaires, except at baseline, were mailed to the 
patients’ homes with a stamped return envelope. During 
the 6-month follow-up, the research nurse contacted the 
patients by telephone every 2 weeks to ask about 
complications, reinterventions, readmissions, visits to the 
outpatient clinic, and missing items in the returned 
quality-of-life questionnaires.
Statistical analysis
The sample size was calculated with the primary outcome 
of global health status. With a two-group t test and a two-
sided signifi cance level of 0·05, we calculated that a 
sample size of 60 patients per group (120 patients in total) 
would have 80% power to detect an eff ect size of 0·5.21,22 
This eff ect size is taken as the default value for a clinically 
signifi cant change on quality-of-life measures in the 
absence of specifi c information.23 Analyses were done by 
intention to treat. Quality-of-life scores from available 
assessments during follow-up were averaged per patient, 
and weighted by the length of the preceding period 
between planned measurements.24 Missing follow-up data 
were regarded as missing at random. Unless otherwise 
stated, diff erences in (weighted) quality-of-life scores 
between the emergency surgery and colonic stenting 
groups were assessed for statistical signifi cance by 
Figure 1: Trial profi le
   51 randomly assigned to receive 
         emergency surgery
         50 had emergency surgery
            1 refused surgery 
  47 randomly assigned to receive colonic stenting
        33 successful stent placements
        14 stent placements failed
              8 guidewires could not pass
              4 strictures seemed to be benign
              1 tumour fistula to small intestine
              1 gastroenterologist’s decision
  98 enrolled and randomly assigned
      1 withdrew informed 
         consent (included 
         until withdrawal)
      5 withdrew informed 
         consent (included 
         until withdrawal)
110 patients assessed for eligibility
      12 declined to participate


















Data are mean (SD) or number. ASA=American Society of Anesthesiologists. 
*Clinical signs of ileus but able to pass fl atus. †Unable to pass fl atus during the last 
24 h before inclusion. 
Table 1: Demographic and clinical characteristics of patients at baseline
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analysis of covariance to adjust for baseline scores. 
Diff erences in procedure-related mortality (at 30 days), 
overall mortality, morbidity, and stoma rates were assessed 
by the χ² test. Diff erences in survival were assessed by the 
Kaplan-Meier log-rank test. All reported p values are two-
sided and were judged to be signifi cant at less than 0·05. 
Analyses were done with SPSS (version 18.0).
The DSMC safeguarded the trial patients with respect 
to safety and eff ectiveness. Morbidity and mortality in the 
experimental group (colonic stenting) was reported to 
the DSMC on short notice. An interim analysis was 
scheduled for after the fi rst 60 treated patients completed 
30 days of follow-up. No formal stopping rule was 
formulated beforehand.
This study is registered, number ISRCTN46462267.17
Role of the funding source
There was no funding source for this study. The 
corresponding author and MGD had full access to all the 
data and the corresponding author had fi nal responsibility 
to submit for publication.
Results
Between March 9, 2007, and Aug 27, 2009, 98 patients 
(mean age 71·0 years [SD 10·8]) were enrolled from 
25 centres and randomly assigned to receive colonic 
stenting or emergency surgery (fi gure 1). Demographic 
and clinical characteristics were balanced between 
treatment groups at baseline (table 1). Two protocol 
violations occurred. One patient refused emergency 
surgery and was treated with a colonic stent followed by 
uneventful elective surgery. One endoscopist refused to 
do endoscopy because of uncertainty about the malignant 
nature of the stricture; this patient received emergency 
surgery, which was complicated by three events (two 
graded as morbidity); the pathology report showed a 
malignant obstruction.
60 patients had been enrolled by Feb 20, 2009, and had 
completed 30 days of follow-up by March 23, 2009. Before 
the planned interim analysis was fi nalised, substantial 
morbidity and some mortality occurred in the colonic 
stenting group. The DSMC was informed and requested 
an additional analysis as soon as 90 patients had 
completed the fi rst month of their follow-up. The study 
was put on hold on Sept 18, 2009, after 98 patients had 
been enrolled, because the DSMC suspected that 
morbidity was higher in the colonic stenting group than 
the emergency surgery group. An independent statistician 
and the principal investigator analysed the data limited to 
30 days of follow-up. The analyses done for 60 and 
90 patients did not show signifi cant diff erences between 
the treatment groups for in-hospital mortality or 30-day 
mortality. However, the colonic stenting group was 
associated with an increased number of patients with 
Colonic stenting* Emergency surgery† Between-group 
diff erence‡
p value
Baseline (nmax=40) Follow-up (nmax=39) Baseline (nmax=42) Follow-up (n=44)
Global health status§ 34·0 (23·2) 63·0 (23·8) 42·5 (28·0) 61·4 (21·9) –4·7 (–14·8 to 5·5) 0·36
Functional scales§
Physical 67·5 (31·3) 67·9 (28·7) 75·4 (28·8) 68·9 (24·1) 0·2 (–11·5 to 11·9) 0·98
Role 39·6 (39·2) 55·5 (30·0) 55·6 (37·8) 57·6 (29·0) 1·0 (–13·3 to 15·4) 0·88
Emotional 57·7 (26·8) 78·3 (23·5) 62·1 (23·3) 78·2 (21·6) –2·2 (–11·7 to 7·2) 0·64
Cognitive 71·7 (27·0) 82·5 (23·9) 75·0 (22·2) 81·3 (17·8) –2·0 (–11·6 to 7·5) 0·67
Social 62·1 (33·1) 76·3 (25·2) 68·7 (33·0) 70·8 (25·8) –7·5 (–18·7 to 3·7) 0·19
Symptom scales§
Fatigue 61·7 (33·9) 42·0 (26·4) 57·0 (30·9) 40·2 (22·9) –1·6 (–13·1 to 9·8) 0·78
Nausea and vomiting 57·1 (34·8) 18·8 (25·7) 48·4 (36·2) 11·6 (16·0) 7·6 (–9·9 to 25·2)¶ 0·39
Pain 72·5 (30·6) 20·9 (24·7) 61·9 (32·6) 18·7 (22·7) –1·5 (–12·3 to 9·4) 0·79
Dyspnoea 25·0 (30·0) 17·5 (26·4) 20·6 (28·5) 16·9 (25·2) –0·9 (–12·6 to 10·8) 0·88
Insomnia 60·8 (38·4) 23·6 (30·0) 44·4 (38·7) 25·4 (27·7) –3·1 (–15·9 to 9·7) 0·63
Appetite loss 69·2 (31·5) 21·2 (30·5) 60·3 (39·8) 24·6 (26·2) 5·6 (–7·4 to 18·7) 0·39
Constipation 86·3 (23·8) 12·3 (26·3) 84·1 (28·7) 6·6 (11·4) –3·9 (–12·2 to 4·4) 0·36
Diarrhoea 20·0 (32·7) 13·2 (18·7) 14·3 (25·7) 11·6 (18·5) –3·2 (–11·8 to 5·4) 0·46
Financial diffi  culties 3·3 (10·1) 11·8 (23·8) 3·3 (12·5) 8·1 (19·6) –2·1 (–11·5 to 7·4) 0·67
Data are mean (SD) or mean diff erence (95% CI). nmax=maximum number of patients with available data. *39–40 patients had data at baseline, 37–39 patients had data at 
follow-up, and 34–36 patients had data at baseline and follow-up. †41–42 patients had data at baseline, 44 patients had data at follow-up, and 38–39 patients had data at 
baseline and follow-up. ‡Value for emergency surgery during follow-up minus colonic stenting during follow-up, based on estimated marginal means with baseline values as 
covariates; nmax=36 patients for colonic stenting and nmax=39 for emergency surgery. §Higher scores on the global health status and functional scales indicate higher quality of 
life; higher scores on the symptom scales indicate lower quality of life. ¶Diff erence represents the change in scores from baseline to follow-up in the emergency surgery group 
minus the colonic stenting group because of violation of the assumption of equality of error variances in the covariance analysis.
Table 2: Diff erences in quality of life during follow-up between patients receiving colonic stenting and emergency surgery, according to EORTC-QLQ-C30, 
based on available data and corrected for diff erences at baseline
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events graded as morbidity at 30-day follow-up, with an 
absolute risk increase of 0·19 (95% CI –0·06 to 0·41; 
relative risk 1·60, 95% CI 0·85 to 3·01) in the interim 
analysis of 60 patients (14 of 28 patients receiving colonic 
stenting vs 10 of 32 receiving emergency surgery), and an 
absolute risk increase of 0·19 (–0·01 to 0·37; relative 
risk 1·62, 0·94 to 2·78) in the interim analysis of 
90 patients (23 of 47 patients vs 13 of 43). After consultation 
with an independent external expert, the DSMC felt 
obliged to stop the trial defi nitively. The trial was offi  cially 
ended on March 12, 2010.
In analysis of the primary outcome, we recorded no 
diff erence in global health status between the treatment 
groups (table 2). Furthermore, we recorded no 
diff erences in the secondary outcomes of mortality and 
morbidity between study groups (table 3). The most 
common serious adverse events were abscess, 
perforation, and anastomotic leakage, and the most 
common adverse events were pneumonia and wound 
infection (table 4). We did not record any signifi cant 
diff erences in cancer-specifi c quality of life (table 2) or 
tumour-specifi c quality of life (table 5) between the 
treatment groups, except for more stoma-related 
problems in the colonic stenting group than in the 
emergency surgery group (table 5). Directly after the 
initial intervention, signifi cantly more patients in the 
emergency surgery group had a stoma (table 3). 
Restoration of bowel continuity was achieved in two of 
24 patients in the colonic stenting group and in fi ve of 
38 patients in the emergency surgery group. 
Anastomotic leakage led to fi ve additional stomata in 
the colonic stenting group and one additional stoma in 
the emergency surgery group. At the latest follow-up, 
27 patients receiving colonic stenting and 34 receiving 
emergency surgery still had a stoma (table 3).
In all patients allocated to receive colonic stenting, with 
the exception of one protocol violation, an attempt to 
place the stent was made within 24 h of randomisation. 
Dilation of the malignant stricture was not done before or 
after stent placement, and forced passage of the stricture 
by the endoscope was not reported in any patients. Stent 
placement was technically successful in 33 of 47 patients 
(fi gure 1). In eight patients a guidewire could not be 
passed along the colonic stricture, four patients seemed 
to have a benign stricture, one patient had a tumour 
fi stula to the small intestine, and one protocol violation, 
described above, occurred.
27 patients received one stent and six patients received 











30-day mortality 5 5 –0·01 (–0·14 to 0·12) 0·92 (0·28 to 2·98) 0·89
Overall mortality 9 9 –0·02 (–0·17 to 0·14) 0·92 (0·40 to 2·12) 0·84
Morbidity* 25 23 –0·08 (–0·27 to 0·11) 0·85 (0·57 to 1·27) 0·43
Stoma rates
Directly after initial intervention 24 38 0·23 (0·04 to 0·40) 1·46 (1·06 to 2·01) 0·016
At latest follow-up 27 34 0·09 (–0·10 to 0·27) 1·16 (0·85 to 1·59) 0·35
Data are number unless otherwise indicated. *Number of patients who had an extended hospital stay or at least one additional hospital admission.







Patients with morbidity* 25 23
Abscess 3 4
Perforation
Guidewire perforations 2 0
Stent-related perforations 4 0
Anastomotic leakage 5 1
Respiratory insuffi  ciency 3 2
Wound dehiscence 2 2
Electrolyte disturbance 1 2
Sepsis 0 3




Organ failure 1 1
Epileptic insult 0 1
Embolism 0 1
Myocardial infarction 0 1
Patients with other adverse events† 8 12
Pneumonia 3 1
Wound infection 1 3
Delirium 2 1
Gastroparesis 0 3
Urinary-tract infection 0 2
Perforation 0 1
Electrolyte disturbance 0 1
Abscess 1 0
Embolism 1 0
*Any event leading to hospital admission or extension of hospital stay (serious 
adverse event). †Adverse events other than serious adverse events.
Table 4: Patients with complications
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total, 31 enteral Wallstents (Boston Scientifi c, Natick, MA, 
USA; diameter 22 mm) and eight WallFlex colonic stents 
(Boston Scientifi c, Natick, MA, USA; diameter 25 mm) 
were placed. 24 stents were 6 cm and 15 were 9 cm in 
length. In all patients who received a colonic stent, the 
obstruction clinically resolved, leading to a clinical success 
of 70%. A procedure-related perforation occurred in 
two patients and a stent-related perforation occurred 
in four patients (table 4).
In total, 110 operations were done by a general surgeon 
(20, 18%) or a colorectal surgeon (87, 79%), and in three 
cases (3%) the surgeon was not traceable. Ultimately, 
78 surgeons did between one and six operations within 
this trial.
In the colonic stenting group, surgery was done in 
31 of 33 patients who underwent technically and clinically 
successful stent placement, whereas the stent served as 
palliative treatment for the remaining two patients. 
These operations were done by colorectal surgeons in 
23 of 31 cases. In 20 patients, a primary anastomosis was 
attempted, which succeeded in 15 patients. In three 
operative specimens, silent stent perforation was 
detected. Across the full colonic stenting group, 
52 operations were done, 41 by colorectal surgeons. 
A primary anastomosis was attempted in 21 patients, but 
in fi ve patients an anastomotic leakage occurred. 
Additionally, a defi nitive stoma was applied in seven 
patients, and a temporary stoma was applied in 
17 patients, two of whom subsequently had bowel 
continuity restored.
All patients in the emergency surgery group, with the 
exception of one protocol violation, were operated on 
within 24 h of randomisation. 41 of 50 emergency 
operations were done by a colorectal surgeon. A primary 
anastomosis was achieved in 12 patients (succeeded 
in 11), a temporary stoma was done in 25 patients, and a 
defi nitive stoma was done in 13 patients.
Eight additional operations were done: one primary 
anastomosis in the patient who had received a colonic 
stent instead of emergency surgery; four restorations of 
bowel continuity in one attempt, and one restoration in 
two attempts; and one stoma creation because of an 
anastomotic leakage. Pathological examination showed 
that in four of 51 patients the stricture was of 
benign origin.
Discussion
In this multicentre randomised trial, colonic stenting or 
emergency surgery did not have any distinct benefi ts for 
global health status, mortality, morbidity, other quality-
of-life dimensions, and stoma rates. These results are 
less favourable than are previous data obtained from 
comparative non-randomised,4,5,13 matched controlled,6,12 
and non-comparative studies14,25 (panel).
We might have selected a population at increased risk 
for complications: 70% of patients presented with a 
Colonic stenting* Emergency surgery† Between-group 
diff erence‡
p value
Baseline (nmax=39) Follow-up (nmax=38) Baseline (nmax=40) Follow-up (nmax=44)
Functional scales§
Body image 76·9 (23·8) 74·5 (23·6) 73·0 (30·8) 74·6 (24·8) –1·4 (–10·8 to 8·0) 0·77
Future perspective 43·0 (35·4) 58·2 (29·4) 41·9 (34·8) 59·4 (27·9) –2·9 (–15·7 to 10·0) 0·66
Sexual functioning 13·7 (20·7) 13·1 (18·6) 12·0 (20·8) 10·6 (15·8) –1·5 (–10·7 to 7·6) 0·74
Sexual enjoyment 35·7 (38·0) 41·6 (39·0) 36·7 (36·7) 28·8 (31·6) –17·6 (–56·5 to 21·3) 0·34
Symptom scales§
Micturition problems 29·2 (19·1) 30·5 (13·0) 22·5 (20·8) 27·1 (14·0) –4·5 (–10·8 to 1·9) 0·17
Chemotherapy side-eff ects 39·5 (28·2) 25·6 (22·7) 35·3 (20·8) 25·2 (19·4) 0·9 (–9·4 to 11·2) 0·87
Gastrointestinal problems 49·9 (15·3) 15·3 (13·9) 40·9 (20·1) 15·7 (13·4) 1·2 (–5·2 to 7·6) 0·71
Male sexual functioning¶ 21·6 (28·1) 25·8 (30·6) 34·4 (42·5) 40·7 (36·3) 5·0 (–13·3 to 23·2) 0·59
Defecation problems 24·2 (15·9) 12·9 (10·3) 22·7 (15·6) 9·2 (6·4) –3·2 (–10·2 to 3·7) 0·35
Stoma-related problems ·· 40·5 (22·6) ·· 28·6 (19·6) –12·0 (–23·7 to –0·2)|| 0·046
Weight loss 45·0 (36·2) 30·8 (29·5) 37·6 (35·2) 25·0 (22·6) –8·5 (–20·7 to 3·8) 0·17
Data are mean (SD) or mean diff erence (95% CI). nmax=maximum number of patients with available data. *14–39 patients had data at baseline, 17–38 had data at follow-up, 
and 7–34 patients had data at baseline and follow-up; reduced numbers of patients with available data resulted from non-response to questionnaire items on sexual 
enjoyment or defecation problems. †10–40 patients had data at baseline, 16–44 patients had data at follow-up, and 6–38 patients had data at baseline and follow-up; 
reduced numbers of patients with available data resulted from non-response to questionnaire items on sexual enjoyment or defecation problems. ‡Value for emergency 
surgery during follow-up minus colonic stenting during follow-up, based on estimated marginal means with baseline values as covariates; nmax=34 for colonic stenting and 
nmax=38 for emergency surgery. §Higher scores on the functional scales indicate higher quality of life; higher scores on the symptom scales indicate lower quality of life.¶Data 
for female sexual functioning are not presented because too few female patients had data at baseline (four each in the colonic stenting and emergency surgery groups), 
follow-up (four in the colonic stenting group, three in the emergency surgery group), and baseline and follow-up (one each in the colonic stenting and emergency surgery 
groups). ||Diff erences in stoma-related problems in 21 patients receiving colonic stenting and 32 receiving emergency surgery are reported for follow-up only.
Table 5: Diff erences in quality of life related to colon cancer during follow-up between patients receiving colonic stenting and emergency surgery, 
according to EORTC-QLQ-CR38, based on available data and corrected for diff erences at baseline
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complete obstruction, which is high in comparison with 
published data (53·8%).25 In patients with a total 
obstruction, stent placement is more diffi  cult27 and the 
bowel might be less easily decompressed than in patients 
with incomplete obstruction, and, therefore, the condition 
of these patients could be suboptimum at time of surgery, 
resulting in a fairly high leak rate if resection without a 
stoma is attempted. In a retrospective study from a 
renowned tertiary referral centre, complete obstruction 
has been identifi ed as a risk factor for complications.25
The quite high morbidity in our study might also 
originate from the meticulous survey of complications 
with telephone calls every 2 weeks during a 6-month 
period and a strict defi nition of morbidity. In addition to 
complications of the initial intervention, we also included 
complications that occurred because of subsequent 
elective operations and all events that led to readmission 
within 6-month follow-up. In most published studies 
with a less strict follow-up, the morbidity rate is probably 
underestimated. To increase our understanding of the 
severity of the complications, we redefi ned them 
according to the Clavien-Dindo classifi cation, a 
frequently used classifi cation system for surgical 
complications (fi gure 2).28
Existing data on colonic stenting as a bridge to surgery 
focuses on technical success, clinical success, 
complications related to placement of the stent, and 
complications related to presence of the stent in the 
colon.5,12,14,25 Our technical success of 70% was rather low 
compared with the published data (91·9%).14 Although 
we requested expert guidance for stent placement, a 
guidewire could not be passed along the colonic stricture 
in eight patients. All endoscopists in our trial were 
experienced in pancreaticobiliary endoscopy, and, 
therefore, are profi cient in colonic stenting,25 possibly 
because they are used to passing guidewires along 
strictures, work with catheters and contrast, and are 
familiar with the placement of metal stents albeit in the 
biliary tract. The fairly high number of patients with a 
complete obstruction might also have lowered the 
technical success. However, our clinical success was in 
accordance with published data.14
Findings of published reports show procedure-related 
and stent-related complications in 5–23·1% of patients, 
with an average of stent-related perforations in 5%.5,12,14,25 
In our population, two (4%) procedure-related and 
four (9%) stent-related complications occurred. We were 
very surprised by the high number of colonic specimens 
showing signs of silent colonic perforation by the 
prosthesis, which increased the total percentage of colon 
perforations to almost 20% (nine perforations in 
47 patients). Pirlet and colleagues26 reported two stent 
perforations and eight silent perforations in 30 patients 
randomised to colonic stenting as a bridge to surgery. 
The oncological consequences of potential tumour 
dissemination caused by perforations are unclear, but the 
















Grade I Grade IVaGrade IIIbGrade IIIaGrade II Grade IVb
Colonic stenting
Emergency surgery
Figure 2: Clavien-Dindo classifi cation of complications28
Panel: Research in context
Systematic review
We searched PubMed, Embase, and the Cochrane Library 
from January, 1990, to January, 2006, for relevant articles by 
use of the search terms “colon” or “colorectal”, “cancer” or 
“malignant”, “acute obstruction” or “stenosis”, “stent” or 
“stenting”, “emergency surgery” or “operation”, and 
“randomised” or “controlled trial”. All languages were 
included. Because no randomised controlled trial could be 
identifi ed, high-grade evidence seemed to be lacking. During 
preparation of this report, the fi rst randomised controlled 
trial of colonic stenting versus emergency surgery was 
published.26
Interpretation
Our trial is, to our knowledge, the largest randomised trial of 
colonic stenting as a bridge to surgery versus emergency 
surgery for allcomers with left-sided malignant colonic 
obstruction in university and non-university teaching 
hospitals. In this setting, colonic stenting has no decisive 
clinical advantages to emergency surgery. These fi ndings are 
consistent with the only other randomised controlled trial in 
this setting.26 Moreover, both trials raise concerns regarding 
overt and silent perforations. Further studies are needed to 
increase data on oncological outcomes and to identify 
specifi c subgroups of patients who might benefi t from 
colonic stenting or emergency surgery.
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perforations should not be disregarded.26 The 
consequences of dissemination could perhaps be derived 
from survival data. However, data from non-randomised 
studies are inconsistent, ranging from no diff erence 
between colonic stenting and emergency surgery to a 
signifi cantly reduced 5-year survival for patients treated 
with colonic stenting before elective surgery.6,29
Another frequently used outcome to assess treatments 
for colonic obstruction is number of ostomies.5,12 In our 
trial, stoma rate was signifi cantly lower in the colonic 
stenting group than in the emergency surgery group 
after initial intervention, but this diff erence had 
disappeared by the end of follow-up. The diff erence was 
partly caused by the high leakage rate of primary 
anastomosis in the stenting group, probably because 
bowel decompression and improvement of the patients’ 
clinical condition were insuffi  cient at the time of elective 
operation. Additionally, the elective nature of the 
operation and the surgeons’ faith in the idea of bridge to 
surgery might have made the surgeons less conservative 
than in the emergency surgery group. Maybe we should 
have lengthened the interval between stent placement 
and elective surgery. The type of surgeon is unlikely to 
have aff ected stoma rate because all patients in whom a 
leakage occurred, with the exception of one, were 
operated on by a colorectal surgeon. The low restoration 
rate of bowel continuity might have been caused by the 
start of chemotherapy in most of our patients directly 
after initial intervention, which might have delayed 
reoperation until after the completion of the trial.
How do our data compare with those in other studies? 
Unfortunately, the primary endpoint cannot be compared 
because we were the fi rst to use quality of life as an 
outcome measure in this setting. With respect to mortality, 
fi ndings of a randomised trial26 and several comparative 
non-randomised or matched controlled studies did not 
show a signifi cant diff erence between colonic stenting 
and emergency surgery,4–6,12 with the exception of a study 
by Park and colleagues.13 Morbidity seemed to be in favour 
of the stenting group in two studies.6,13 With respect to 
stoma rate, signifi cantly more primary anastomosis was 
recorded in the stenting group than in the emergency 
surgery group in non-randomised studies.4–6,12 By contrast, 
in the randomised trial, 17 of 30 patients in the emergency 
surgery group and 13 of 30 patients in the colonic stenting 
group sustained a stoma (p=0·30).26
Our study design has some shortcomings. First, quite a 
large number of hospitals actively recruited patients, 
ranging from one to 17 patients per centre. While 
designing the study, we considered limiting enrolment 
and endoscopic treatment to tertiary referral centres, but 
this restriction would have made the results unsuitable for 
translation to clinical practice. Second, in the emergency 
surgery group, all but one of the patients received the 
allocated treatment, whereas six patients in the colonic 
stenting group did not seem to have an indication for stent 
placement (fi gure 1). In the four patients in whom the 
lesion seemed to be benign at endoscopy, the procedure 
was ceased and endoscopists did not attempt to place the 
stent. Because of frail evidence of the benefi t of stenting in 
benign colonic strictures, and the likelihood of a high 
occurrence of complications in patients with acute 
diverticular disease who receive a colonic stent,30 we aimed 
to exclude these patients from our population by requiring 
sound images of the colon before enrolment. However, we 
could not achieve complete exclusion of patients with 
benign colonic strictures without pathological confi rmation 
before stent placement, and such confi rmation was, in 
our opinion, not feasible because of the importunate 
character of an acute colonic obstruction. Therefore, we 
reasoned that refraining from stent placement in these 
patients would be best.
Third, a cost-eff ectiveness analysis, including costs per 
quality-adjusted life-year as an outcome measure, was 
planned alongside this randomised trial. In view of advice 
from the DSMC, we decided to refrain from judgment 
about the economic viability of colonic stenting when 
safety was possibly at stake. Last, our trial was ended 
early, implying a loss of statistical power because the 
sample size was smaller than expected. However, the 
similarity in global health status, mortality, morbidity, 
other quality-of-life dimensions, and stoma rates between 
treatment groups suggests that the probability of colonic 
stenting becoming more eff ective than emergency 
surgery is negligible.
The fi ndings of this randomised trial did not show that 
colonic stenting as a bridge to surgery was better than 
emergency surgery for all comers with left-sided malignant 
colonic obstruction in university and non-university 
teaching hospitals. Our data cannot be extrapolated to 
specifi c groups of patients—eg, those at high risk of 
complications from operations because of old age or 
obesity, or those with colonic obstruction of low severity—
or to expert centres in colonic stent placement. In our 
opinion, colonic stenting can be used as an alternative to 
emergency surgery, but should be used with caution, 
mainly because of concerns of overt and silent perforations. 
Future studies need to further investigate oncological 
outcomes and establish whether specifi c groups of patients 
could have a greater benefi t from either colonic stenting 
or emergency surgery.25
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